JPRN-UMIN000021954
Recruiting
N/A
Examination of the efficacy of dapagliflozin in patients with type 2 diabetes - Efficacy of dapagliflozin
Tonami general hospital Department of diabetes mellitus and endocrinology0 sites200 target enrollmentMay 1, 2016
ConditionsType 2 diabetes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Tonami general hospital Department of diabetes mellitus and endocrinology
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients with hypersensitivity to an ingredient of dapagliflozin 2\.Diabetic ketoacidosis 3\.Past history of coma or severe hypoglycemia 4\.Severe infection or serious trauma 5\.Severe liver injury, renal failure, cardiac disease, proliferative retinopathy 6\.Past history of cerebral infarction 7\.Past history of malignant tumor 8\.Women with during pregnancy, nursing, or pregnant likelihood 9\.Inadequate patients judged by doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-PLAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-DKAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-BGAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500
Completed
Phase 3
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330